Lunai Bioworks Swings to $1.02M Profit in H1 FY2026 After $51.5M Loss Year Earlier
Lunai Bioworks Inc. reported net income of $1.02 million for the six months ending December 31, 2025, reversing a $51.5 million loss in the prior-year period. Operating expenses dropped 91% to $5.1 million.
Lunai Bioworks Inc. reported net income of $1.02 million for the six months ending December 31, 2025, a sharp reversal from a net loss of $51.5 million in the same period a year earlier. The Delaware-based biotech company cut operating expenses 91% to $5.1 million from $57.9 million. Read more earnings reports.
For the three months ending December 31, 2025, the company posted a net loss of $1.8 million, narrower than the $7.3 million loss reported in the prior-year quarter. Operating expenses for the quarter fell to $1.8 million from $4.5 million.
General and administrative expenses totaled $4.2 million for the six-month period, down from substantially higher levels in the prior year. Research and development spending dropped to $70,279 from $551,273.
Cash and cash equivalents stood at $491,645 as of December 31, 2025, up from $92,700 at the end of the prior fiscal year on June 30, 2025. The company burned $2.4 million in operations during the six months, compared with $4.6 million in the year-earlier period.
Total assets declined to $6.7 million from $8.2 million at fiscal year-end. The company carried $20.2 million in total liabilities as of December 31, 2025, down from $29.6 million six months prior.
Stockholders' deficit narrowed to $13.5 million from $21.3 million at June 30, 2025. The accumulated deficit stood at $509.4 million as of December 31, 2025, compared with $510.5 million at the prior fiscal year-end.
Lunai Bioworks reported basic and diluted earnings per share of $0.04 for the six months ending December 31, 2025, versus a loss of $3.20 per share in the prior-year period. The company had 24.2 million common shares outstanding as of December 31, 2025, up from 17.7 million at June 30, 2025.
| Financial Metric | H1 FY2026 (Jul-Dec 2025) | H1 FY2025 (Jul-Dec 2024) |
|---|---|---|
| Net Income (Loss) | $1,019,617 | -$51,464,429 |
| Operating Expenses | $5,131,774 | $57,884,869 |
| Cash from Operations | -$2,420,323 | -$4,576,052 |
| Total Assets | $6,666,446 | N/A |
| Cash & Equivalents | $491,645 | $311,764 |
| EPS (Basic) | $0.04 | -$3.20 |
The company raised $2.3 million from financing activities during the six-month period, compared with $4.6 million in the prior year. It generated $543,462 from investing activities.
Property, plant, and equipment fell to $13,253 as of December 31, 2025, from $367,843 six months earlier. Goodwill remained unchanged at $6.0 million.